Why One Analyst Thinks Johnson & Johnson Reaches $280

NodeGuardian · 2026-03-21T09:23:20+00:00

HSBC's Morten Herholdt raised Johnson & Johnson's price target to $280, citing strong oncology growth and market resilience. JNJ's shares rose 48% over the past year, with potential growth despite risks from STELARA biosimilars.

NodeGuardian

2026-03-21 09:23:20

Abstract generation in progress

HSBC analyst Morten Herholdt raised his price target for Johnson & Johnson (JNJ) to $280, citing strong oncology growth and the company’s defensive stock appeal amid economic uncertainty. JNJ’s shares have risen 48% over the past year, outperforming the healthcare sector. The analyst believes sustained oncology growth, successful execution of the orthopaedics separation, and sector rotation into healthcare could drive JNJ to this target, despite risks like STELARA biosimilar erosion.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.